To assess the performance of a Deep Neural Network (DNN)-based prototype algorithm for automated PE detection on CTPA scans. Patients who had previously undergone CTPA with three different systems (SOMATOM Force, go.Top, and Definition AS; Siemens Healthineers, Forchheim, Germany) because of suspected PE from September 2022 to January 2023 were retrospectively enrolled in this study (n = 1,000, 58.8 % women). For detailed evaluation, all PE were divided into three location-based subgroups: central arteries, lobar branches, and peripheral regions. Clinical reports served as ground truth. Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and accuracy were determined to evaluate the performance of DNN-based PE detection. Cases were excluded due to incomplete data (n = 32), inconclusive report (n = 17), insufficient contrast detected in the pulmonary trunk (n = 40), or failure of the preprocessing algorithms (n = 8). Therefore, the final cohort included 903 cases with a PE prevalence of 12 % (n = 110). The model achieved a sensitivity, specificity, PPV, and NPV of 84.6, 95.1, 70.5, and 97.8 %, respectively, and delivered an overall accuracy of 93.8 %. Among the false positive cases (n = 39), common sources of error included lung masses, pneumonia, and contrast flow artifacts. Common sources of false negatives (n = 17) included chronic and subsegmental PEs. The proposed DNN-based algorithm provides excellent performance for the detection of PE, suggesting its potential utility to support radiologists in clinical reading and exam prioritization.

Glioblastoma (GBM), primary central nervous system lymphoma (PCNSL), and brain metastases (BM) are common malignant brain tumors with similar radiological features, while the accurate and non-invasive dialgnosis is essential for selecting appropriate treatment plans. This study develops a deep learning model, FoTNet, to improve the automatic diagnosis accuracy of these tumors, particularly for the relatively rare PCNSL tumor. The model integrates a frequency-based channel attention layer and the focal loss to address the class imbalance issue caused by the limited samples of PCNSL. A multi-center MRI dataset was constructed by collecting and integrating data from Sir Run Run Shaw Hospital, along with public datasets from UPENN and TCGA. The dataset includes T1-weighted contrast-enhanced (T1-CE) MRI images from 58 GBM, 82 PCNSL, and 269 BM cases, which were divided into training and testing sets with a 5:2 ratio. FoTNet achieved a classification accuracy of 92.5 % and an average AUC of 0.9754 on the test set, significantly outperforming existing machine learning and deep learning methods in distinguishing among GBM, PCNSL, and BM. Through multiple validations, FoTNet has proven to be an effective and robust tool for accurately classifying these brain tumors, providing strong support for preoperative diagnosis and assisting clinicians in making more informed treatment decisions.

Computer-aided diagnosis systems based on deep neural networks heavily rely on datasets with high-quality labels. However, manual annotation for lesion diagnosis relies on image features, often requiring professional experience and complex image analysis process. This inevitably introduces noisy labels, which can misguide the training of classification models. Our goal is to design an effective method to address the challenges posed by label noise in medical images. we propose a novel noise-tolerant medical image classification framework consisting of two phases: fore-training correction and progressive hard-sample enhanced learning. In the first phase, we design a dual-branch sample partition detection scheme that effectively classifies each instance into one of three subsets: clean, hard, or noisy. Simultaneously, we propose a hard-sample label refinement strategy based on class prototypes with confidence-perception weighting and an effective joint correction method for noisy samples, enabling the acquisition of higher-quality training data. In the second phase, we design a progressive hard-sample reinforcement learning method to enhance the model's ability to learn discriminative feature representations. This approach accounts for sample difficulty and mitigates the effects of label noise in medical datasets. Our framework achieves an accuracy of 82.39% on the pneumoconiosis dataset collected by our laboratory. On a five-class skin disease dataset with six different levels of label noise (0, 0.05, 0.1, 0.2, 0.3, and 0.4), the average accuracy over the last ten epochs reaches 88.51%, 86.64%, 85.02%, 83.01%, 81.95%, 77.89%, respectively; For binary polyp classification under noise rates of 0.2, 0.3, and 0.4, the average accuracy over the last ten epochs is 97.90%, 93.77%, 89.33%, respectively. The effectiveness of our proposed framework is demonstrated through its performance on three challenging datasets with both real and synthetic noise. Experimental results further demonstrate the robustness of our method across varying noise rates.

Patients with metastatic bone disease are at risk of pathological femoral fractures and may require prophylactic surgical fixation. Current clinical decision support tools often overestimate fracture risk, leading to overtreatment. While novel scores integrating femoral strength assessment via finite element (FE) models show promise, they require 3D imaging, extensive computation, and are difficult to automate. Predicting femoral strength directly from single 2D radiographic projections using convolutional neural networks (CNNs) could address these limitations, but this approach has not yet been explored for femora with metastatic lesions. This study aimed to test whether CNNs can accurately predict strength of femora with metastatic lesions from single 2D radiographic projections. CNNs with various architectures were developed and trained using an FE model generated training dataset. This training dataset was based on 36,000 modified computed tomography (CT) scans, created by randomly inserting artificial lytic lesions into the CT scans of 36 intact anatomical femoral specimens. From each modified CT scan, an anterior-posterior 2D projection was generated and femoral strength in one-legged stance was determined using nonlinear FE models. Following training, the CNN performance was evaluated on an independent experimental test dataset consisting of 31 anatomical femoral specimens (16 intact, 15 with artificial lytic lesions). 2D projections of each specimen were created from corresponding CT scans and femoral strength was assessed in mechanical tests. The CNNs' performance was evaluated using linear regression analysis and compared to 2D densitometric predictors (bone mineral density and content) and CT-based 3D FE models. All CNNs accurately predicted the experimentally measured strength in femora with and without metastatic lesions of the test dataset (R²≥0.80, CCC≥0.81). In femora with metastatic lesions, the performance of the CNNs (best: R²=0.84, CCC=0.86) was considerably superior to 2D densitometric predictors (R²≤0.07) and slightly inferior to 3D FE models (R²=0.90, CCC=0.94). CNNs, trained on a large dataset generated via FE models, predicted experimentally measured strength of femora with artificial metastatic lesions with accuracy comparable to 3D FE models. By eliminating the need for 3D imaging and reducing computational demands, this novel approach demonstrates potential for application in a clinical setting.

Prior to the commencement of treatment, it is essential to establish an objective method for accurately predicting the prognosis of patients with hepatocellular carcinoma (HCC) undergoing transarterial chemoembolization (TACE). In this study, we aimed to develop a machine learning (ML) model to predict the response of HCC patients to TACE based on CT images analysis. Public dataset from The Cancer Imaging Archive (TCIA), uploaded in August 2022, comprised a total of 105 cases, including 68 males and 37 females. The external testing dataset was collected from March 1, 2019 to July 1, 2022, consisting of total of 26 patients who underwent TACE treatment at our institution and were followed up for at least 3 months after TACE, including 22 males and 4 females. The public dataset was utilized for ResNet50 transfer learning and ML model construction, while the external testing dataset was used for model performance evaluation. All CT images with the largest lesions in axial, sagittal, and coronal orientations were selected to construct 2.5D images. Pre-trained ResNet50 weights were adapted through transfer learning to serve as a feature extractor to derive deep features for building ML models. Model performance was assessed using area under the curve (AUC), accuracy, F1-Score, confusion matrix analysis, decision curves, and calibration curves. The AUC values for the external testing dataset were 0.90, 0.90, 0.91, and 0.89 for random forest classifier (RFC), support vector classifier (SVC), logistic regression (LR), and extreme gradient boosting (XGB), respectively. The accuracy values for the external testing dataset were 0.79, 0.81, 0.80, and 0.80 for RFC, SVC, LR, and XGB, respectively. The F1-score values for the external testing dataset were 0.75, 0.77, 0.78, and 0.79 for RFC, SVC, LR, and XGB, respectively. The ML model constructed using deep features from 2.5D images has the potential to be applied in predicting the prognosis of HCC patients following TACE treatment.

The objective of the present study was to determine the accuracy of machine learning (ML) models in the detection of mesiobuccal (MB2) canals in axial cone-beam computed tomography (CBCT) sections. A total of 2500 CBCT scans from the oral radiology department of University Dental Hospital, Sharjah were screened to obtain 277 high-resolution, small field-of-view CBCT scans with maxillary molars. Among the 277 scans, 160 of them showed the presence of MB2 orifice and the rest (117) did not. Two-dimensional axial images of these scans were then cropped. The images were classified and labelled as N (absence of MB2) and M (presence of MB2) by 2 examiners. The images were embedded using Google's Inception V3 and transferred to the ML classification model. Six different ML models (logistic regression [LR], naïve Bayes [NB], support vector machine [SVM], K-nearest neighbours [Knn], random forest [RF], neural network [NN]) were then tested on their ability to classify the images into M and N. The classification metrics (area under curve [AUC], accuracy, F1-score, precision) of the models were assessed in 3 steps. NN (0.896), LR (0.893), and SVM (0.886) showed the highest values of AUC with specified target variables (steps 2 and 3). The highest accuracy was exhibited by LR (0.849) and NN (0.848) with specified target variables. The highest precision (86.8%) and recall (92.5%) was observed with the SVM model. The success rates (AUC, precision, recall) of ML algorithms in the detection of MB2 were remarkable in our study. It was also observed that when the target variable was specified, significant success rates such as 86.8% in precision and 92.5% in recall were achieved. The present study showed promising results in the ML-based detection of MB2 canal using axial CBCT slices.

AI has emerged as a transformative force in clinical medicine, changing the diagnosis, treatment, and management of patients. Tools have been derived for working with ML, DL, and NLP algorithms to analyze large complex medical datasets with unprecedented accuracy and speed, thereby improving diagnostic precision, treatment personalization, and patient care outcomes. For example, CNNs have dramatically improved the accuracy of medical imaging diagnoses, and NLP algorithms have greatly helped extract insights from unstructured data, including EHRs. However, there are still numerous challenges that face AI integration into clinical workflows, including data privacy, algorithmic bias, ethical dilemmas, and problems with the interpretability of "black-box" AI models. These barriers have thus far prevented the widespread application of AI in health care, and its possible trends, obstacles, and future implications are necessary to be systematically explored. The purpose of this paper is, therefore, to assess the current trends in AI applications in clinical medicine, identify those obstacles that are hindering adoption, and identify possible future directions. This research hopes to synthesize evidence from other peer-reviewed articles to provide a more comprehensive understanding of the role that AI plays to advance clinical practices, improve patient outcomes, or enhance decision-making. A systematic review was done according to the PRISMA guidelines to explore the integration of Artificial Intelligence in clinical medicine, including trends, challenges, and future directions. PubMed, Cochrane Library, Web of Science, and Scopus databases were searched for peer-reviewed articles from 2014 to 2024 with keywords such as "Artificial Intelligence in Medicine," "AI in Clinical Practice," "Machine Learning in Healthcare," and "Ethical Implications of AI in Medicine." Studies focusing on AI application in diagnostics, treatment planning, and patient care reporting measurable clinical outcomes were included. Non-clinical AI applications and articles published before 2014 were excluded. Selected studies were screened for relevance, and then their quality was critically appraised to synthesize data reliably and rigorously. This systematic review includes the findings of 8 studies that pointed out the transformational role of AI in clinical medicine. AI tools, such as CNNs, had diagnostic accuracy more than the traditional methods, particularly in radiology and pathology. Predictive models efficiently supported risk stratification, early disease detection, and personalized medicine. Despite these improvements, significant hurdles, including data privacy, algorithmic bias, and resistance from clinicians regarding the "black-box" nature of AI, had yet to be surmounted. XAI has emerged as an attractive solution that offers the promise to enhance interpretability and trust. As a whole, AI appeared promising in enhancing diagnostics, treatment personalization, and clinical workflows by dealing with systemic inefficiencies. The transformation potential of AI in clinical medicine can transform diagnostics, treatment strategies, and efficiency. Overcoming obstacles such as concerns about data privacy, the danger of algorithmic bias, and difficulties with interpretability may pave the way for broader use and facilitate improvement in patient outcomes while transforming clinical workflows to bring sustainability into healthcare delivery.

Global aging raises concerns about cognitive health, metabolic disorders, and sarcopenia. Prevention of reversible decline and diseases in middle-aged individuals is essential for promoting healthy aging. We hypothesize that changes in body composition, specifically muscle mass and visceral fat, and metabolic indices are associated with accelerated brain aging. To explore these relationships, we employed a brain age model to investigate the links between the brain age gap (BAG), body composition, and metabolic markers. Using T1-weighted anatomical brain MRIs, we developed a machine learning model to predict brain age from gray matter features, trained on 2,675 healthy individuals aged 18-92 years. This model was then applied to a separate cohort of 458 Taiwanese adults (57.8 years ± 11.6; 280 men) to assess associations between BAG, body composition quantified by MRI, and metabolic markers. Our model demonstrated reliable generalizability for predicting individual age in the clinical dataset (MAE = 6.11 years, r = 0.900). Key findings included significant correlations between larger BAG and reduced total abdominal muscle area (r = -0.146, p = 0.018), lower BMI-adjusted skeletal muscle indices, (r = -0.134, p = 0.030), increased systemic inflammation, as indicated by high-sensitivity C-reactive protein levels (r = 0.121, p = 0.048), and elevated fasting glucose levels (r = 0.149, p = 0.020). Our findings confirm that muscle mass and metabolic health decline are associated with accelerated brain aging. Interventions to improve muscle health and metabolic control may mitigate adverse effects of brain aging, supporting healthier aging trajectories.

Artificial intelligence (AI) may extract prognostic information from MRI for localized prostate cancer. We evaluate whether AI-derived prostate and gross tumor volume (GTV) are associated with toxicity and oncologic outcomes after radiotherapy. We conducted a retrospective study of patients, who underwent radiotherapy between 2010 and 2017. We trained an AI segmentation algorithm to contour the prostate and GTV from patients treated with external-beam RT, and applied the algorithm to those treated with brachytherapy. AI prostate and GTV volumes were calculated from segmentation results. We evaluated whether AI GTV volume was associated with biochemical failure (BF) and metastasis. We evaluated whether AI prostate volume was associated with acute and late grade 2+ genitourinary toxicity, and International Prostate Symptom Score (IPSS) resolution for monotherapy and combination sets, separately. We identified 187 patients who received brachytherapy (monotherapy (N = 154) or combination therapy (N = 33)). AI GTV volume was associated with BF (hazard ratio (HR):1.28[1.14,1.44];p < 0.001) and metastasis (HR:1.34[1.18,1.53;p < 0.001). For the monotherapy subset, AI prostate volume was associated with both acute (adjusted odds ratio:1.16[1.07,1.25];p < 0.001) and late grade 2 + genitourinary toxicity (adjusted HR:1.04[1.01,1.07];p = 0.01), but not IPSS resolution (0.99[0.97,1.00];p = 0.13). For the combination therapy subset, AI prostate volume was not associated with either acute (p = 0.72) or late (p = 0.75) grade 2 + urinary toxicity. However, AI prostate volume was associated with IPSS resolution (0.96[0.93, 0.99];p = 0.01). AI-derived prostate and GTV volumes may be prognostic for toxicity and oncologic outcomes after RT. Such information may aid in treatment decision-making, given differences in outcomes among RT treatment modalities.

To investigate the impacts of a deep learning-based iterative reconstruction algorithm on image quality and measuring accuracy of bone mineral density (BMD) in low-dose chest CT. Phantom and patient studies were separately conducted in this study. The same low-dose protocol was used for phantoms and patients. All images were reconstructed with filtered back projection, hybrid iterative reconstruction (HIR) (KARL®, level of 3,5,7), and deep learning-based iterative reconstruction (artificial intelligence iterative reconstruction [AIIR], low, medium, and high strength). The noise power spectrum (NPS) and the task-based transfer function (TTF) were evaluated using phantom. The accuracy and the relative error (RE) of BMD were evaluated using a European spine phantom. The subjective evaluation was performed by 2 experienced radiologists. BMD was measured using quantitative CT (QCT). Image noise, signal-to-noise ratio (SNR), contrast-to-noise ratio (CNR), BMD values, and subjective scores were compared with Wilcoxon signed-rank test. The Cohen's kappa test was used to evaluate the inter-reader and inter-group agreement. AIIR reduced noise and improved resolution on phantom images significantly. There were no significant differences among BMD values in all groups of images (all P > 0.05). RE of BMD measured using AIIR images was smaller. In objective evaluation, all strengths of AIIR achieved less image noise and higher SNR and CNR (all P < 0.05). AIIR-H showed the lowest noise and highest SNR and CNR (P < 0.05). The increase in AIIR algorithm strengths did not affect BMD values significantly (all P > 0.05). The deep learning-based iterative reconstruction did not affect the accuracy of BMD measurement in low-dose chest CT while reducing image noise and improving spatial resolution. The BMD values could be measured accurately in low-dose chest CT with deep learning-based iterative reconstruction while reducing image noise and improving spatial resolution.